PURPOSE: To evaluate the reliability of the autoimmune bullous diseases quality of life (ABQOL) questionnaire in a North American patient cohort. METHODS: Patients attending the dermatology clinics of the University of Pennsylvania with a histological diagnosis of an autoimmune bullous disease (AIBD) and self-reported proficiency in English were recruited to participate in the study. Patients completed the ABQOL questionnaire at Day 0 and Day 3. Internal consistency was calculated through Cronbach's alpha. Test-retest reliability was determined by the intraclass correlation coefficient. RESULTS: Of the 45 patients enrolled in the study, 39 patients (87 %) participated to completion. The mean age was 60.7 years with an equal sex distribution observed. Patients had a range of AIBD including pemphigus vulgaris, bullous pemphigoid, pemphigus foliaceus, epidermolysis bullosa acquisita, mucous membrane pemphigoid and linear IgA disease. Cronbach's alpha was calculated to be 0.90. The intraclass correlation coefficient was calculated to be 0.93 (95 % confidence interval 0.88-0.94). CONCLUSION: The ABQOL was found to be reliable tested by internal consistency and test-retest reliability in an American patient cohort. It represents a promising disease-specific outcome measure for patients with AIBD.
PURPOSE: To evaluate the reliability of the autoimmune bullous diseases quality of life (ABQOL) questionnaire in a North American patient cohort. METHODS:Patients attending the dermatology clinics of the University of Pennsylvania with a histological diagnosis of an autoimmune bullous disease (AIBD) and self-reported proficiency in English were recruited to participate in the study. Patients completed the ABQOL questionnaire at Day 0 and Day 3. Internal consistency was calculated through Cronbach's alpha. Test-retest reliability was determined by the intraclass correlation coefficient. RESULTS: Of the 45 patients enrolled in the study, 39 patients (87 %) participated to completion. The mean age was 60.7 years with an equal sex distribution observed. Patients had a range of AIBD including pemphigus vulgaris, bullous pemphigoid, pemphigus foliaceus, epidermolysis bullosa acquisita, mucous membrane pemphigoid and linear IgA disease. Cronbach's alpha was calculated to be 0.90. The intraclass correlation coefficient was calculated to be 0.93 (95 % confidence interval 0.88-0.94). CONCLUSION: The ABQOL was found to be reliable tested by internal consistency and test-retest reliability in an American patient cohort. It represents a promising disease-specific outcome measure for patients with AIBD.
Authors: C A C Prinsen; J de Korte; M Augustin; F Sampogna; S S Salek; M K A Basra; E A Holm; T E C Nijsten Journal: J Eur Acad Dermatol Venereol Date: 2013-01-09 Impact factor: 6.166
Authors: Susan Clemens; Nelufa Begum; Catherine Harper; Jennifer A Whitty; Paul A Scuffham Journal: Qual Life Res Date: 2014-03-28 Impact factor: 4.147
Authors: Misha Rosenbach; Dedee F Murrell; Jean-Claude Bystryn; Sam Dulay; Sarah Dick; Steve Fakharzadeh; Russell Hall; Neil J Korman; Julie Lin; Joyce Okawa; Amit G Pandya; Aimee S Payne; Mathew Rose; David Rubenstein; David Woodley; Carmela Vittorio; Benjamin B Werth; Erik A Williams; Lynne Taylor; Andrea B Troxel; Victoria P Werth Journal: J Invest Dermatol Date: 2009-04-09 Impact factor: 8.551
Authors: Deshan F Sebaratnam; Anna Marie Hanna; Shien-ning Chee; John W Frew; Supriya S Venugopal; Benjamin S Daniel; Linda K Martin; Lesley M Rhodes; Jeremy Choon Kai Tan; Charles Qian Wang; Belinda Welsh; Tamar Nijsten; Dédée F Murrell Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282
Authors: Rebecca L Krain; Carolyn J Kushner; Meera Tarazi; Rebecca G Gaffney; Andrea C Yeguez; Danielle E Zamalin; David R Pearson; Rui Feng; Aimee S Payne; Victoria P Werth Journal: Front Immunol Date: 2019-11-06 Impact factor: 7.561
Authors: H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth Journal: J Eur Acad Dermatol Venereol Date: 2021-07-10 Impact factor: 6.166